NEW YORK ( TheStreet) -- Genzyme Corporation (Nasdaq: GENZ) hit a new 52-week high Wednesday as it traded at $75.35 compared with its previous 52-Week high of $74.95. Genzyme is changing hands at $75.29 with 9.3 million shares traded as of 9:31 a.m. ET. Average volume has been 2.9 million shares over the past 30 days. Genzyme has a market cap of $18.6 billion and is part of the health care sector and drugs industry. Shares are up 4.3% year to date as of the close of trading on Tuesday. Genzyme Corporation operates as a biotechnology company worldwide. It focuses on rare genetic disease disorders, renal diseases, orthopaedics, cancers, transplant and immune diseases, and diagnostic and predictive testing areas. TheStreet Ratings rates Genzyme as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and weak operating cash flow. You can view the full Genzyme Ratings Report. See all 52-week high stocks or get investment ideas from our investment research center.